Navigation Links
Another industry first enabled by Benchmark Biolabs - Peros' oral delivery platform and vaccine facility licensed by the USDA
Date:4/15/2008

LINCOLN, NE, April 15 /PRNewswire/ - The acceptance of Peros' oral delivery platform and vaccine facility by the USDA marks another significant achievement by Benchmark Biolabs, a full service biopharmaceutical product development firm.

Benchmark Biolabs designed, constructed and oversees the operation and management of the Peros production facility which is co-located on Benchmark's R&D and manufacturing biotechnology campus in Lincoln, NE.

By obtaining approval by the USDA, Peros, a pioneering biotechnology company that has developed unique natural product formulation methods enabling oral delivery of biopharmaceutical compounds, is now well positioned to begin product commercialization of its oral delivery platform.

"Had it not been for Benchmark's stage-gated "BEAM(TM)" approach to our project from validation to licensure, our technology would have been yet another promising biotech discovery that would never have reached its commercial potential.", stated Dr. Grant Vandenberg, CSO and Founder of Peros.

Benchmark and Peros are excited to offer this first-in-class oral delivery technology platform that will significantly enhance the actual value of vaccines. The licensed platform offers a labor minimizing, practical method for oral delivery of prophylactic and therapeutic products for the livestock industry as well as traditional animal health company opportunities to expand the oral enablement of the industry as a whole.

"Benchmark's mission is to design and implement, with our clients, an efficient product development process - delivering critical expertise, technologies, facilities, ideas and services, in a seamless and integrated offering", added Tom Overbay, Vice-President of Business Development for Benchmark Biolabs.

Peros' licensure marks another significant and innovative first obtained by Benchmark over their 11-year history. At the Benchmark campus there are now three licensed manufacturing facilities which were designed, built, and managed using the BEAM(TM) model for enabling biotechnology in stage-gated manner. Each of these facilities sprang from a novel, unique technology which was heavily reliant on the development process offered by Benchmark. Along with development of traditional biologicals, Benchmark has been intimately involved with molecular farming to produce a parasite vaccine and commercial development of a tissue culture based plant-derived recombinant protein production system..

"Enabling technology is not specific to the nature of an asset but rather to the focused and prioritized implementation of key regulatory steps toward commercialization. In addition to the routine business at Benchmark Biolabs, we have initiated the setup and operation of five separate biotech institutions covering a wide array of biotechniques, molecules, and regulatory compliance. That is a new company nearly every 2 years since the inception of Benchmark Biolabs and demonstrates the business niche of enabling bio-molecules rather than simply discovering them." said Tim Miller, President of Benchmark Biolabs.

About Benchmark

Benchmark Biolabs is a biopharmaceutical product development firm with over a decade of success in the validation and development of biologicals. Benchmark applies a unique mindset to the development process, offering a modern business strategy aimed at integrating the entire process, from Concept to Commercialization.

Benchmark's team provides analytical, clinical, (including a BSL-3) custom laboratory, regulatory process development, manufacturing and QC services in order to enhance the optimal data sets and efficiency of product development for our clients.


'/>"/>
SOURCE Benchmark Biolabs
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Signalife Receives Another $3.3 Million Sales Orders
2. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
3. 2007 Another Record Year in Terms of Sales and Earnings for Gerresheimer
4. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
8. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
9. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
10. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
11. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 AquaBounty Technologies, Inc. (AIM: ABTU; ... in aquaculture and a majority-owned subsidiary of Intrexon Corporation ... completed the listing of its common shares on the ... Intrexon. "AquaBounty,s listing on NASDAQ represents an ... exposure to the U.S. markets as we advance plans ...
(Date:1/19/2017)... ... ... FireflySci Inc. is a go-getter type of company that continues to grow ... main factors. The first is the amazing customer service that the FireflySci staff ... around the world. , 2016 was a tremendous sales year for FFS and much ...
(Date:1/19/2017)... Md. , Jan. 18, 2017  Northwest Biotherapeutics, ... developing DCVax® personalized immune therapies for operable and inoperable ... Bosch , Chief Technical Officer of NW Bio, will ... January 19, 2017, at the Hyatt Regency Hotel in ... Bosch will chair the session entitled "New Therapeutic Approaches ...
(Date:1/18/2017)... ... 18, 2017 , ... Opal Kelly, a leading producer of ... announced the ZEM5310 USB 3.0 FPGA Module, combining a SuperSpeed USB 3.0 interface ... factor suitable for prototyping, testing, and production-ready integration. The ZEM5310 USB interface delivers ...
Breaking Biology Technology:
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, Inc., ... in healthy volunteers of a novel calcium release-activated ... acute pancreatitis. Acute pancreatitis, sudden ... mild disorder, but can be very serious.  In severe ... sepsis, where extended hospital stays, time in the ...
(Date:1/6/2017)... , Jan. 5, 2017  Delta ID Inc., a ... scanning technology for automotive at CES® 2017. Delta ID ... ) to demonstrate the use of iris scanning as ... authenticate the driver in a car, and as a ... driving experience. Delta ID and Gentex will ...
(Date:1/4/2017)... , Jan. 4, 2017  CES 2017 – ... biometric sensor technology, today announced the launch of ... sensor systems, the highly-accurate biometric sensor modules that ... biometric technology, experience and expertise. The two new ... designed specifically for hearables, and Benchmark BW2.0, a ...
Breaking Biology News(10 mins):